CN104066448A - 眼病的治疗 - Google Patents

眼病的治疗 Download PDF

Info

Publication number
CN104066448A
CN104066448A CN201280054482.8A CN201280054482A CN104066448A CN 104066448 A CN104066448 A CN 104066448A CN 201280054482 A CN201280054482 A CN 201280054482A CN 104066448 A CN104066448 A CN 104066448A
Authority
CN
China
Prior art keywords
ecd
hptp
antibody
hptpβ
bonding agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280054482.8A
Other languages
English (en)
Chinese (zh)
Inventor
K.彼得斯
R.沙尔维茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aerpio Therapeutics LLC
Original Assignee
Aerpio Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aerpio Therapeutics LLC filed Critical Aerpio Therapeutics LLC
Priority to CN201710084072.2A priority Critical patent/CN107080843A/zh
Publication of CN104066448A publication Critical patent/CN104066448A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201280054482.8A 2011-10-13 2012-10-15 眼病的治疗 Pending CN104066448A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710084072.2A CN107080843A (zh) 2011-10-13 2012-10-15 眼病的治疗

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161546708P 2011-10-13 2011-10-13
US61/546708 2011-10-13
PCT/US2012/060263 WO2013056233A1 (en) 2011-10-13 2012-10-15 Treatment of ocular disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201710084072.2A Division CN107080843A (zh) 2011-10-13 2012-10-15 眼病的治疗

Publications (1)

Publication Number Publication Date
CN104066448A true CN104066448A (zh) 2014-09-24

Family

ID=48082580

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201710084072.2A Pending CN107080843A (zh) 2011-10-13 2012-10-15 眼病的治疗
CN201280054482.8A Pending CN104066448A (zh) 2011-10-13 2012-10-15 眼病的治疗

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201710084072.2A Pending CN107080843A (zh) 2011-10-13 2012-10-15 眼病的治疗

Country Status (11)

Country Link
US (5) US8999325B2 (enExample)
EP (2) EP2766044B1 (enExample)
JP (5) JP2014532072A (enExample)
CN (2) CN107080843A (enExample)
AU (1) AU2012323849B2 (enExample)
BR (1) BR112014008759A8 (enExample)
CA (1) CA2850824C (enExample)
ES (1) ES2774972T3 (enExample)
HK (2) HK1201196A1 (enExample)
MX (1) MX347226B (enExample)
WO (1) WO2013056233A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106491911A (zh) * 2016-10-24 2017-03-15 严成 一种治疗脉络膜血管瘤的中药
CN109715189A (zh) * 2016-07-20 2019-05-03 爱尔皮奥治疗有限公司 靶向VE-PTP(HPTP-β)的人源化单克隆抗体
CN112322719A (zh) * 2020-11-06 2021-02-05 温州医科大学 循环血外泌体miRNA作为视网膜静脉阻塞疾病诊断标志物中的应用
CN114341177A (zh) * 2019-08-06 2022-04-12 豪夫迈·罗氏有限公司 眼科疾病的个性化治疗
US12043664B2 (en) 2011-10-13 2024-07-23 EyePoint Pharmaceuticals, Inc. Methods for treating vascular leak syndrome and cancer

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007237096C1 (en) 2006-04-07 2012-12-13 EyePoint Pharmaceuticals, Inc. Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
CN105412094A (zh) 2009-07-06 2016-03-23 爱尔皮奥治疗有限公司 用于防止癌细胞转移的化合物、组合物和方法
ES2424122T3 (es) 2009-11-06 2013-09-27 Aerpio Therapeutics Inc. Inhibidores de la prolilhidroxilasa
CN107080843A (zh) 2011-10-13 2017-08-22 爱尔皮奥治疗有限公司 眼病的治疗
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
HK1206558A1 (en) 2013-03-15 2016-01-15 Aerpio Therapeutics Inc Compositions, formulations and methods for treating ocular diseases
CN105164157B (zh) 2013-04-29 2024-05-28 豪夫迈·罗氏有限公司 Fc-受体结合的修饰的非对称抗体及使用方法
WO2015107015A1 (en) 2014-01-15 2015-07-23 F. Hoffmann-La Roche Ag Fc-region variants with improved protein a-binding
EP3094649A1 (en) * 2014-01-15 2016-11-23 F. Hoffmann-La Roche AG Fc-region variants with modified fcrn-binding properties
CN106232120B (zh) 2014-02-19 2021-01-08 爱尔皮奥治疗有限公司 制备n-苄基-3-羟基-4-取代的-吡啶-2-(1h)-酮的方法
EP3116503A4 (en) 2014-03-14 2017-08-23 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
WO2016022813A1 (en) 2014-08-07 2016-02-11 Aerpio Therapeutics, Inc. Combination of immunotherapies with activators of tie-2
WO2016049183A1 (en) * 2014-09-24 2016-03-31 Aerpio Therapeutics, Inc. Ve-ptp extracellular domain antibodies delivered by a gene therapy vector
ES2981607T3 (es) 2015-09-23 2024-10-09 Eyepoint Pharmaceuticals Inc Activadores de Tie-2 para uso en el tratamiento de la presión intraocular
CN109996440A (zh) * 2016-10-21 2019-07-09 曼宁研究有限公司 Ve-ptp敲除
JP7695187B2 (ja) 2018-09-24 2025-06-18 アイポイント ファーマシューティカルズ， インコーポレイテッド ＨＰＴＰ－β（ＶＥ－ＰＴＰ）およびＶＥＧＦを標的にする多特異性抗体
AU2020264969B2 (en) 2019-04-29 2025-06-05 EyePoint Pharmaceuticals, Inc. Tie-2 activators targeting the schlemm's canal
GB2589400A (en) 2019-06-24 2021-06-02 Aerpio Pharmaceuticals Inc Formulations of tie-2 activators and methods of use thereof
KR20250010199A (ko) * 2023-07-11 2025-01-21 재단법인 아산사회복지재단 Tie2을 과발현하는 혈관내피세포를 포함하는 망막 내 혈관신생 질환 예방 또는 치료용 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070059762A1 (en) * 2003-05-29 2007-03-15 Kazushi Araki Insulin resistance curative and method of screening the same
CN101506183A (zh) * 2006-06-27 2009-08-12 宝洁公司 人蛋白酪氨酸磷酸酶抑制剂及其使用方法
CN101802002A (zh) * 2006-04-07 2010-08-11 宝洁公司 结合人蛋白酪氨酸磷酸酶β（HPTPβ）的抗体及其用途
US20100256147A1 (en) * 2007-04-13 2010-10-07 Hangauer Jr David G Biaryl acetamide derivatives as modulators of the kinase cascade for the treatment of hearing loss, osteoporosis and cell proliferation disorders

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
ES2273415T3 (es) * 1997-04-07 2007-05-01 Genentech, Inc. Anticuerpos anti-vegf.
ATE241380T1 (de) 1999-03-26 2003-06-15 Regeneron Pharma Modulierung der gefässepermeabilität mittels tie2 rezeptoraktivatoren
EP1046715A1 (en) * 1999-04-23 2000-10-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Interaction of vascular-endothelial protein-tyrosine phosphatase with the angiopoietin receptor tie-2
HRP20030041A2 (en) 2000-06-23 2005-02-28 Schering Aktiengesellschaft Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor fuction and their use (ii)
US6316109B1 (en) 2000-09-21 2001-11-13 Ppg Industries Ohio, Inc. Aminoplast-based crosslinkers and powder coating compositions containing such crosslinkers
CN1318093C (zh) * 2001-09-28 2007-05-30 参天制药株式会社 含与聚乙二醇结合的药物的眼组织注射剂
US20030158083A1 (en) * 2002-02-08 2003-08-21 The Procter & Gamble Company Method of effecting angiogenesis by modulating the function of a novel endothelia phosphatase
US7507568B2 (en) 2002-09-25 2009-03-24 The Proctor & Gamble Company Three dimensional coordinates of HPTPbeta
US7226755B1 (en) 2002-09-25 2007-06-05 The Procter & Gamble Company HPTPbeta as a target in treatment of angiogenesis mediated disorders
US20050059639A1 (en) 2003-09-11 2005-03-17 Wei Edward T. Ophthalmic compositions and method for treating eye discomfort and pain
US20080267971A1 (en) 2004-12-21 2008-10-30 Green Larry L Antibodies Directed to Angiopoietin-2 and Uses Thereof
JP2006210811A (ja) * 2005-01-31 2006-08-10 Nippon Steel Chem Co Ltd プリント配線板の製造方法
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
WO2007033216A2 (en) 2005-09-12 2007-03-22 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
US20090123474A1 (en) 2005-12-15 2009-05-14 Astrazeneca Ab Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or fltl antagonist for treating cancer
US7589212B2 (en) 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US20130023542A1 (en) 2006-06-27 2013-01-24 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US7795444B2 (en) 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
US8846685B2 (en) 2006-06-27 2014-09-30 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
CA2690244C (en) * 2007-06-26 2016-08-09 Ofra Benny-Ratsaby Metap-2 inhibitor polymersomes for therapeutic administration
ES2540854T3 (es) 2007-06-29 2015-07-14 Merck Sharp & Dohme Corp. Usos de antagonistas MDL-1
CN101827523A (zh) * 2007-08-16 2010-09-08 马库赛特公司 用于治疗眼部疾病或病症的制剂
MX2010004327A (es) 2007-10-22 2010-05-13 Schering Corp Anticuerpos anti-vegf completamente humanos y metodos de uso.
US8293714B2 (en) * 2008-05-05 2012-10-23 Covx Technology Ireland, Ltd. Anti-angiogenic compounds
SG172312A1 (en) * 2009-01-12 2011-07-28 Akebia Therapeutics Inc Methods for treating vascular leak syndrome
US9096555B2 (en) 2009-01-12 2015-08-04 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome
US8883832B2 (en) 2009-07-06 2014-11-11 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
CN105412094A (zh) 2009-07-06 2016-03-23 爱尔皮奥治疗有限公司 用于防止癌细胞转移的化合物、组合物和方法
US20180092883A1 (en) 2010-10-07 2018-04-05 Aerpio Therapeutics, Inc. Phosphatase inhibitors for treating ocular diseases
NZ610230A (en) 2010-10-07 2015-07-31 Aerpio Therapeutics Inc Compositions and methods for treating ocular edema, neovascularization and related diseases
CN107080843A (zh) 2011-10-13 2017-08-22 爱尔皮奥治疗有限公司 眼病的治疗
US20130095065A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for Treating Vascular Leak Syndrome and Cancer
HK1206558A1 (en) 2013-03-15 2016-01-15 Aerpio Therapeutics Inc Compositions, formulations and methods for treating ocular diseases
AU2017299581B2 (en) * 2016-07-20 2024-05-23 EyePoint Pharmaceuticals, Inc. Humanized monoclonal antibodies that target ve-ptp (hptp-β)
JP7695187B2 (ja) * 2018-09-24 2025-06-18 アイポイント ファーマシューティカルズ， インコーポレイテッド ＨＰＴＰ－β（ＶＥ－ＰＴＰ）およびＶＥＧＦを標的にする多特異性抗体

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070059762A1 (en) * 2003-05-29 2007-03-15 Kazushi Araki Insulin resistance curative and method of screening the same
CN101802002A (zh) * 2006-04-07 2010-08-11 宝洁公司 结合人蛋白酪氨酸磷酸酶β（HPTPβ）的抗体及其用途
CN101506183A (zh) * 2006-06-27 2009-08-12 宝洁公司 人蛋白酪氨酸磷酸酶抑制剂及其使用方法
US20100256147A1 (en) * 2007-04-13 2010-10-07 Hangauer Jr David G Biaryl acetamide derivatives as modulators of the kinase cascade for the treatment of hearing loss, osteoporosis and cell proliferation disorders

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12043664B2 (en) 2011-10-13 2024-07-23 EyePoint Pharmaceuticals, Inc. Methods for treating vascular leak syndrome and cancer
CN109715189A (zh) * 2016-07-20 2019-05-03 爱尔皮奥治疗有限公司 靶向VE-PTP(HPTP-β)的人源化单克隆抗体
US12145986B2 (en) 2016-07-20 2024-11-19 EyePoint Pharmaceuticals, Inc. Method of treating an ocular condition by administering a humanized monoclonal antibodies that target VE-PTP (HPTP-Beta)
CN106491911A (zh) * 2016-10-24 2017-03-15 严成 一种治疗脉络膜血管瘤的中药
CN114341177A (zh) * 2019-08-06 2022-04-12 豪夫迈·罗氏有限公司 眼科疾病的个性化治疗
CN112322719A (zh) * 2020-11-06 2021-02-05 温州医科大学 循环血外泌体miRNA作为视网膜静脉阻塞疾病诊断标志物中的应用

Also Published As

Publication number Publication date
CN107080843A (zh) 2017-08-22
EP3501536B1 (en) 2025-12-24
US10329357B2 (en) 2019-06-25
HK1201438A1 (en) 2015-09-04
EP2766044B1 (en) 2019-12-11
US20180044432A1 (en) 2018-02-15
EP3501536A1 (en) 2019-06-26
MX347226B (es) 2017-04-19
JP2018131467A (ja) 2018-08-23
US8999325B2 (en) 2015-04-07
US20200231703A1 (en) 2020-07-23
HK1201196A1 (en) 2015-08-28
WO2013056233A1 (en) 2013-04-18
JP2016210811A (ja) 2016-12-15
NZ623275A (en) 2016-05-27
BR112014008759A2 (pt) 2017-06-13
CA2850824C (en) 2023-01-03
US20200010565A1 (en) 2020-01-09
JP6259503B2 (ja) 2018-01-10
AU2012323849A1 (en) 2014-04-17
JP2016210812A (ja) 2016-12-15
JP2014532072A (ja) 2014-12-04
EP2766044A4 (en) 2015-06-10
ES2774972T3 (es) 2020-07-23
AU2012323849B2 (en) 2017-04-20
BR112014008759A8 (pt) 2017-09-12
US20130095105A1 (en) 2013-04-18
US20150232575A1 (en) 2015-08-20
JP2018131466A (ja) 2018-08-23
MX2014004449A (es) 2014-11-10
EP2766044A1 (en) 2014-08-20
CA2850824A1 (en) 2013-04-18

Similar Documents

Publication Publication Date Title
US10329357B2 (en) Treatment of ocular disease
AU2007238677B2 (en) Use of IL-I antibodies for treating ophthalmic disorders
US20100111963A1 (en) Method for treating age-related macular degeneration
AU2011224224B2 (en) Humanized and chimeric anti-properdin antibodies
NZ623275B2 (en) Treatment of ocular disease
AU2011101622B4 (en) Method for treating intraocular neovascular diseases
HK1102106B (en) Method for treating intraocular neovascular diseases

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1201196

Country of ref document: HK

C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: ohio

Applicant after: Akebia Therapeutics Inc.

Address before: ohio

Applicant before: A Erpiao therapeutics limited company

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: AERPIO THERAPEUTICS INC. TO: AKEBIA THERAPEUTICS INC.

Free format text: CORRECT: ADDRESS; FROM:

RJ01 Rejection of invention patent application after publication

Application publication date: 20140924

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1201196

Country of ref document: HK